To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.
David Smith, CEO Galapagos Services, commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
